|
|
Volumn 95, Issue 5, 2002, Pages 1064-1070
|
|
Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy
a
|
|
Author keywords
Acute myelogenous leukemia (AML); Clinical outcome; financial charges; Financial data; Investigational (protocol) therapy; Standard therapy
|
|
Indexed keywords
CYTARABINE;
GRANULOCYTE COLONY STIMULATING FACTOR;
IDARUBICIN;
ACUTE GRANULOCYTIC LEUKEMIA;
ADULT;
AGED;
ARTICLE;
BLOOD TRANSFUSION;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
FEMALE;
GENETIC RISK;
HEALTH CARE COST;
HUMAN;
MALE;
MEDICARE;
PATIENT CARE;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
RETROSPECTIVE STUDY;
ADULT;
AGE FACTORS;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS;
FEMALE;
HEALTH CARE COSTS;
HEALTH STATUS;
HUMANS;
LEUKEMIA, MYELOCYTIC, ACUTE;
MALE;
MIDDLE AGED;
RETROSPECTIVE STUDIES;
RISK FACTORS;
|
|
EID: 0036721204
PISSN: 0008543X
EISSN: None
Source Type: Journal
DOI: 10.1002/cncr.10805 Document Type: Article |
|
Times cited : (5)
|
|
References (5)
|
